ICER President Steve Pearson expresses interest in setting drug costs for accelerated approval drugs low with price increases based on confirmatory evidence ahead of upcoming white paper from the group.

International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.

Formal MACPAC proposal to US Congress to consider enhanced rebates for drugs approved via the Accelerated Approval pathway could have a long shelf life in the context of debates over drug pricing – and over FDA regulatory reforms.

First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.

Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.

Trade group’s new agenda offers few original solutions to tackle US drug costs, relying on old standbys and reminders of what medical innovation might be lost if industry is financially targeted by policy makers with a strong nod to drug manufacturers role the current pandemic.

A lot of new drugs aren’t really all that innovative, which complicates the view that lower profitability will mean less biopharma innovation.

Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.

As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.